[go: up one dir, main page]

WO2009079452A3 - Treatment and prevention of hiv infection - Google Patents

Treatment and prevention of hiv infection Download PDF

Info

Publication number
WO2009079452A3
WO2009079452A3 PCT/US2008/086821 US2008086821W WO2009079452A3 WO 2009079452 A3 WO2009079452 A3 WO 2009079452A3 US 2008086821 W US2008086821 W US 2008086821W WO 2009079452 A3 WO2009079452 A3 WO 2009079452A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv infection
downmodulating
hdf
subject
hdfs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/086821
Other languages
French (fr)
Other versions
WO2009079452A2 (en
Inventor
Stephen Elledge
Judy Lieberman
Abraham L. Brass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
General Hospital Corp
Boston Childrens Hospital
Original Assignee
Brigham and Womens Hospital Inc
General Hospital Corp
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, General Hospital Corp, Immune Disease Institute Inc filed Critical Brigham and Womens Hospital Inc
Priority to CA2708658A priority Critical patent/CA2708658A1/en
Priority to EP08860890A priority patent/EP2231176A2/en
Priority to AU2008338526A priority patent/AU2008338526A1/en
Priority to US12/747,041 priority patent/US20100273859A1/en
Publication of WO2009079452A2 publication Critical patent/WO2009079452A2/en
Publication of WO2009079452A3 publication Critical patent/WO2009079452A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are methods for treating and/or preventing HIV infection in a cell. The methods involve downmodulating one or more of the HIV-dependency factors (HDFs) disclosed herein to thereby treat and/or prevent HIV infection in the cell. Downmodulating the HDFs can be by contacting the cell with an agent that downmodulates the HDF. Also disclosed herein are methods for treating and/or preventing HIV infection in a subject comprising downmodulating one or more of the HIV-dependency factors (HDFs), disclosed herein, to thereby treat and/or prevent HIV infection in the subject. The method may further comprise selecting a subject diagnosed with or at risk for HIV infection, prior to downmodulating. Downmodulating the HDFs may comprise administering an agent that downmodulates the HDF to the subject such that the agent contacts HIV host cells of the subject. The agent may inhibit HDF gene expression, protein synthesis, HDF function or HDF activity, or combinations thereof.
PCT/US2008/086821 2007-12-14 2008-12-15 Treatment and prevention of hiv infection Ceased WO2009079452A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2708658A CA2708658A1 (en) 2007-12-14 2008-12-15 Treatment and prevention of hiv infection
EP08860890A EP2231176A2 (en) 2007-12-14 2008-12-15 Treatment and prevention of hiv infection
AU2008338526A AU2008338526A1 (en) 2007-12-14 2008-12-15 Treatment and prevention of HIV infection
US12/747,041 US20100273859A1 (en) 2007-12-14 2008-12-15 Treatment and prevention of hiv infection

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US776607P 2007-12-14 2007-12-14
US61/007,766 2007-12-14
US1115708P 2008-01-15 2008-01-15
US61/011,157 2008-01-15
US19500608P 2008-10-02 2008-10-02
US61/195,006 2008-10-02

Publications (2)

Publication Number Publication Date
WO2009079452A2 WO2009079452A2 (en) 2009-06-25
WO2009079452A3 true WO2009079452A3 (en) 2009-09-17

Family

ID=40796114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086821 Ceased WO2009079452A2 (en) 2007-12-14 2008-12-15 Treatment and prevention of hiv infection

Country Status (5)

Country Link
US (1) US20100273859A1 (en)
EP (1) EP2231176A2 (en)
AU (1) AU2008338526A1 (en)
CA (1) CA2708658A1 (en)
WO (1) WO2009079452A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1534340E (en) 2002-09-06 2012-03-13 Cerulean Pharma Inc Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
BRPI0911332A2 (en) * 2008-04-04 2019-09-24 Calando Pharmaceuticals Inc compositions and use of epas1 inhibitors
US20120041051A1 (en) * 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
EP2448961A2 (en) * 2009-06-30 2012-05-09 Université de Liège Targets for retrovirus associated diseases
US9522943B2 (en) 2012-03-02 2016-12-20 Rhode Island Hospital, A Lifespan-Partner Treating human immunodeficiency virus infections
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US11564937B2 (en) 2017-07-11 2023-01-31 Sanford Burnham Prebys Medical Discovery Institute Nucleoporins as drug targets for anti-proliferative therapeutics
KR20190013635A (en) * 2017-07-28 2019-02-11 주식회사 레모넥스 Pharmaceutical composition for preventing or treating hepatocellular carcinoma
US20220339192A1 (en) * 2019-09-07 2022-10-27 Themba Inc. Gene editing for viral infections
WO2023232983A1 (en) 2022-06-01 2023-12-07 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024023267A2 (en) * 2022-07-27 2024-02-01 E-Therapeutics Plc Nucleic acid compounds
CN117660339B (en) * 2023-10-25 2025-03-18 首都医科大学附属北京同仁医院 A method for constructing a dry eye cell model based on mitochondrial dysfunction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040029123A1 (en) * 2000-03-15 2004-02-12 Alexander Olek Diagnosis of diseases associated with the cell cycle
US20070254329A1 (en) * 2002-05-02 2007-11-01 Rubin Donald H Mammalian Genes Involved in Viral Infection and Tumor Suppression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002309100A1 (en) * 2001-03-12 2002-11-18 Proteologics, Ltd. Compositions and methods for the modulation of viral maturation
AU2003224725A1 (en) * 2002-03-20 2003-10-08 Brigham And Women's Hospital, Inc. Hiv therapeutic
US20090182134A1 (en) * 2002-11-14 2009-07-16 Dharmacon, Inc. siRNA targeting phosphatases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029123A1 (en) * 2000-03-15 2004-02-12 Alexander Olek Diagnosis of diseases associated with the cell cycle
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20070254329A1 (en) * 2002-05-02 2007-11-01 Rubin Donald H Mammalian Genes Involved in Viral Infection and Tumor Suppression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEIBERT, C. ET AL.: "Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs", CURR PHARM DES., vol. 10, no. 17, 2004, pages 2041 - 2062, XP008137823 *

Also Published As

Publication number Publication date
AU2008338526A1 (en) 2009-06-25
CA2708658A1 (en) 2009-06-25
US20100273859A1 (en) 2010-10-28
WO2009079452A2 (en) 2009-06-25
EP2231176A2 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
WO2009079452A3 (en) Treatment and prevention of hiv infection
WO2007005453A3 (en) Compositions for treating or preventing obesity and insulin resistance disorders
WO2007079203A3 (en) Treatment for cutaneous t cell lymphoma
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
WO2008124384A3 (en) Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
WO2007033281A3 (en) Ion exchange resin treated to control swelling
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
WO2005065667A3 (en) Compositions for treating or preventing obesity and insulin resistance disorders
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
WO2006074308A3 (en) Regeneration of pancreatic islets by amniotic fluid stem cell therapy
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
WO2013001372A3 (en) Methods and compositions for inhibition of activation of regulatory t cells
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2009108706A3 (en) Methods for inhibiting six 1 and eya proteins
WO2006096565A3 (en) Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
WO2007146730A3 (en) Deacetylase inhibitor therapy
WO2007117560A8 (en) Piperidine and morpholine renin inhibitors
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2008147483A3 (en) Neurogenic compounds
WO2012068339A3 (en) Methods of treating cancer
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
HK1203823A1 (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2008063639A3 (en) Compositions and methods for preserving cells of the eye
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2006053161A8 (en) Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08860890

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2708658

Country of ref document: CA

Ref document number: 12747041

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008338526

Country of ref document: AU

Date of ref document: 20081215

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008860890

Country of ref document: EP